Barometer Capital Management Inc. acquired a new stake in shares of argenex SE (NASDAQ:ARGX – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 1,550 shares of the company’s stock, valued at approximately $1,132,000.
Other institutional investors have also recently made changes to their positions in the company. Abound Wealth Management lifted its position in shares of argenex by 3,200.0% in the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after buying an additional 32 shares in the last quarter. Sound Income Strategies LLC purchased a new position in argenex during the 4th quarter valued at approximately $28,000. Whipplewood Advisors LLC purchased a new position in argenex during the 1st quarter valued at approximately $28,000. Sunbelt Securities Inc. bought a new stake in argenex in the 3rd quarter worth approximately $36,000. Finally, Aventura Private Wealth LLC bought a new stake in argenex in the 4th quarter worth approximately $38,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.
argenex Trading Up 3.4%
Shares of NASDAQ ARGX opened at $874.74 on Wednesday. argenex SE has a 12-month low of $563.08 and a 12-month high of $953.58. The stock’s fifty day simple moving average is $862.87 and its two-hundred day simple moving average is $813.72. The stock has a market capitalization of $54.72 billion, a PE ratio of 38.95, a price-to-earnings-growth ratio of 1.05 and a beta of 0.45.
Analyst Ratings Changes
ARGX has been the subject of a number of research reports. Oppenheimer lowered their target price on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a research report on Thursday, April 2nd. HC Wainwright restated a “buy” rating and issued a $940.00 price target on shares of argenex in a research report on Thursday, June 25th. Royal Bank Of Canada upped their price target on shares of argenex from $890.00 to $945.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Wedbush reiterated an “outperform” rating and set a $1,000.00 price objective on shares of argenex in a research report on Thursday, June 11th. Finally, Guggenheim boosted their target price on shares of argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,042.67.
Read Our Latest Research Report on argenex
argenex Company Profile
argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.
The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.
Featured Stories
- Five stocks we like better than argenex
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
